The combination of empagliflozin and linagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. Shares of Zydus Lifesciences Ltd ended at ₹936.50, down by ₹3.95, or 0.42%, on the BSE today, November 27.
